One day's eurozone optimism is the next day's Grexit panic. Yesterday's hopes for bold action during a meeting of European leaders have evaporated as investors prepare for a seemingly inevitable ejection of Greece from the euro. Taken by itself, Greece returning to the drachma is not the end of the world, but it could prove to be a Lehman Brothers event, setting off a chain reaction that could lead to runs on Italy and Spain, ending the euro and massively disrupting global capital markets. Scary stuff.
With that in mind, let's take a closer look at how the major indexes are faring and drill down on a few stocks making headlines.
Dow Jones Industrial Average (INDEX: ^DJI)
Source: Yahoo! Finance.
It's a bloodbath for the three major indexes, as all were off more than 1% earlier today. The Nasdaq has gained back ground the fastest, despite tech's relative dive compared to the other major sectors. Dell (NAS: DELL) is crashing, as investors saw over 17% of their holding's value evaporate thanks to a weak forecast that at the high end of the range sees $15 billion of revenue versus an anticipated $15.4 billion. Dow component Hewlett-Packard (NYS: HPQ) , which reports on Wednesday, has seen an index-leading 5% decline as the difficult market will exacerbate an already-challenging quarter. Intel (NAS: INTC) , the world's biggest chip maker, is also down over 3% as its focus on the PC market (versus mobile) could weigh on future results.
I think Dell and other PC-focused companies are on the wrong side of a long-term tech trend, but losing $4.7 billion in market cap for an approximately $400 million-$700 million top-line miss screams of a market overreaction. These aren't growth companies, but as Windows 8 releases, they should see an uptick in demand as corporations modernize their equipment. Problems in Europe have likely made customers cautious of outlays, but between short-term headwinds and long-term challenges, there could be a chance for investors to profit.
In health care news, GlaxoSmithKline has threatened to kill its offer to buy partner Human Genome Sciences (NAS: HGSI) after the latter adopted a poison pill. The $13 offer is unchanged, and HGS is reportedly seeking other strategic alternatives (read: buyers), but the company just doesn't have much appeal to anyone but Glaxo. The two share Benlysta, a lupus treatment that has been slow to launch, as well as two other intriguing phase 3 drugs for cardiovascular disease and type 2 diabetes. While Glaxo could sweeten the bid, I wouldn't expect much of a bump between now and June 7 when the deal expires. No one ever went broke taking profits.
Get yourself into the market
Motley Fool co-founder David Gardner's recently identified a small-cap health-care company that is poised for monster returns, thanks to its game-changing product already on the market. To uncover this top pick today, take a look at our special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Access your report -- it's totally free.
At the time thisarticle was published David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Intel. Motley Fool newsletter services have recommended buying shares of Dell and Intel. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.